AI-generated analysis. Always verify with the original filing.
EyePoint Pharmaceuticals, Inc. announced Q4 and full-year 2025 financial results with total net revenue of $0.6 million and $31.4 million, respectively, and net losses of $67.6 million and $232.0 million. The company reported $306 million in cash providing runway into Q4 2027, Phase 3 trial progress for DURAVYU in wet AMD and DME, and appointed Michael Campbell as Chief Commercial Officer.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 4, 2026, EyePoint, Inc. (the “Company”) issued a press release announcing its financial results for the
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of EyePoint, Inc., dated March 4, 2026 104 Cover Page Interactive Da
Michael Campbell
Effective: N/A
to lead launch strategy and readiness for DURAVYU